Abstract: AIM: To investigate the effects of rosiglitazone on lipid and visfatin in patients with type 2 diabetes mellitus (T2DM) and analysis its clinical efficacy.METHODS: A total of 84 patients with T2DM were enrolled in this study. All cases were divided into control group (n=42) and rosiglitazone treatment group (n=42). Before and after the treatment, FPG, Hbalc, TC, TG, LDL, HDL, visfatin and other biochemical indicators were compared.RESULTS: Before treatment, FPG, Hbalc, TC, TG, LDL , HDL and visfatin had no significant difference between the two groups (P>0.05). After treatment, FPG and Hbalc expression level were significantly reduce (P<0.05, P<0.01), the rosiglitazone group FPG and Hbalc reduce amplitude were significantly higher than that control group (P<0.05). Before and after treatment, treatment group TC, TG, LDL, HDL and visfatin expression difference was not statistically significant (P>0.05), the treatment group TC, TG, LDL and visfatin express were significantly lower than before treatment (P<0.05, P<0.01), HDL were significantly higher than before treatment (P<0.05). Rosiglitazone group clinical efficient (95.2%) were higher than that control group (P<0.05). The adverse reaction rates of rosiglitazone group (23.8%) and control group (21.4%) showed no significant difference (P>0.05).CONCLUSION: Rosiglitazone treatment showed more effective to reduce the serum level of glucose, lipid and visfatin, with the low rate of adverse reactions.

Key words: Type 2 diabetes mellitus, Rosiglitazone, Visfatin, Lipid